CONTACT US   |  (864) 397-5101

Nephron Works to Resolve Nationwide Drug Shortage by Producing Vital Medications

503B nephron

Nephron 503B Outsourcing Facility, a division of Nephron Pharmaceuticals Corporation, is focused on resolving drug shortage concerns with the production of 0.5% Albuterol 5 mL, del Nido Cardioplegia, Lidocaine 1% and Succinylcholine products.

The following medications are readily available for order through the Nephron online ordering portal:

  • 0.5% Albuterol 25 mg/5 mL (5 mg/mL) Preservative Free
  • del Nido Cardioplegia Solution 1000 mL
  • Lidocaine Injection Vial, USP 1% 50 mg/5 mL (10 mg/mL) Preservative Free
  • Succinylcholine Chloride Injection, USP 200 mg/10 mL (20 mg/mL) Preservative Free

“As a nationwide leader in manufacturing lifesaving medication, we work hard every single day to help the federal government alleviate drug shortages – and to deliver hospitals and patients the treatments they deserve and expect in a timely manner,” said Lou Kennedy, CEO and Owner of Nephron. “Playing this vital role in manufacturing is all the motivation we need to do our jobs well – and stay focused on precisely what it takes to raise the bar not only for our team, but for manufacturers everywhere.”

Nephron has over 25 years of sterile pharmaceutical manufacturing experience and operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes, luer-lock vials, IV bottles and IV bags for hospitals across America.

To place an order, customers can contact Nephron directly at NOFaccounts@nephronpharm.com or 1-844-224-2225.

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.